ENXTPA:ALPAT

Stock Analysis Report

Executive Summary

Plant Advanced Technologies SA, a plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France.

Snowflake

Fair value with mediocre balance sheet.

Rewards

PE ratio (17.5x) is below the French market (17.9x)

Revenue is forecast to grow 15.43% per year

ALPAT became profitable this year

Risk Analysis

Earnings are forecast to decline by an average of -91.2% per year for the next 3 years

Has a high level of debt

Large one-off items impacting financial results

Shareholders have been diluted in the past year

+ 2 more risks

Share Price & News

How has Plant Advanced Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALPAT has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.6%

ALPAT

-2.9%

FR Biotechs

0.01%

FR Market


1 Year Return

-14.0%

ALPAT

-34.4%

FR Biotechs

17.5%

FR Market

Return vs Industry: ALPAT exceeded the French Biotechs industry which returned -34.4% over the past year.

Return vs Market: ALPAT underperformed the French Market which returned 17.5% over the past year.


Shareholder returns

ALPATIndustryMarket
7 Day-0.6%-2.9%0.01%
30 Day-9.4%3.0%4.4%
90 Day-7.2%-13.1%8.0%
1 Year-14.0%-14.0%-34.3%-34.4%21.4%17.5%
3 Year-19.6%-19.6%-59.5%-59.5%49.8%35.5%
5 Year-53.3%-53.3%-62.8%-63.4%66.6%43.0%

Price Volatility Vs. Market

How volatile is Plant Advanced Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Plant Advanced Technologies undervalued compared to its fair value and its price relative to the market?

17.5x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALPAT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ALPAT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ALPAT is good value based on its PE Ratio (17.5x) compared to the Biotechs industry average (40.4x).

PE vs Market: ALPAT is good value based on its PE Ratio (17.5x) compared to the French market (17.9x).


Price to Earnings Growth Ratio

PEG Ratio: ALPAT's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: ALPAT is good value based on its PB Ratio (1.8x) compared to the FR Biotechs industry average (1.9x).


Next Steps

Future Growth

How is Plant Advanced Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-91.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALPAT's earnings are forecast to decline over the next 3 years (-91.2% per year).

Earnings vs Market: ALPAT's earnings are forecast to decline over the next 3 years (-91.2% per year).

High Growth Earnings: ALPAT's earnings are forecast to decline over the next 3 years.

Revenue vs Market: ALPAT's revenue (15.4% per year) is forecast to grow faster than the French market (4.7% per year).

High Growth Revenue: ALPAT's revenue (15.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALPAT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Plant Advanced Technologies performed over the past 5 years?

32.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALPAT has large one-off items impacting its financial results.

Growing Profit Margin: ALPAT became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: ALPAT has become profitable over the past 5 years, growing earnings by 32.5% per year.

Accelerating Growth: ALPAT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ALPAT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: ALPAT's Return on Equity (10.9%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Plant Advanced Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: ALPAT's short term assets (€3.4M) exceeds its short term liabilities (€2.7M)

Long Term Liabilities: ALPAT's short term assets (€3.4M) exceeds its long term liabilities (2.2M)


Debt to Equity History and Analysis

Debt Level: ALPAT's debt to equity ratio (46.4%) is considered high.

Reducing Debt: ALPAT's debt to equity ratio has reduced from 58.8% to 46.4% over the past 5 years.

Debt Coverage: Insufficient data to determine if ALPAT's debt is well covered by operating cash flow.

Interest Coverage: Insufficient data to determine if ALPAT's interest payments on its debt are well covered by EBIT.


Balance Sheet

Inventory Level: ALPAT has a high level of physical assets or inventory.

Debt Coverage by Assets: ALPAT's debt is not covered by short term assets (assets are 0.9x debt).


Next Steps

Dividend

What is Plant Advanced Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%4.5%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate ALPAT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ALPAT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALPAT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALPAT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALPAT's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

What is the CEO of Plant Advanced Technologies's salary, the management and board of directors tenure and is there insider trading?

€61k

CEO Compensation


CEO

Jean-Paul Fevre (65yo)

0yrs

Tenure

€60,630

Compensation

Mr. Jean-Paul Fevre serves as the Chief Executive Officer and Chairman of Plant Advanced Technologies SA. 


CEO Compensation Analysis

Compensation vs Market: Jean-Paul's total compensation ($USD0.00) is below average for companies of similar size in the French market ($USD158.12K).

Compensation vs Earnings: Jean-Paul's compensation has been consistent with company performance over the past year.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.6%.


Management Team

  • Frederic Bourgaud (55yo)

    Vice-Chairman of the Board of Directors & Deputy CEO

    • Tenure: 0yrs
    • Compensation: €11.81k
  • Paul Hannewald (39yo)

    Deputy Chief Executive Officer and Director

    • Tenure: 0yrs
    • Compensation: €53.14k
  • Jean-Paul Fevre (65yo)

    Chairman & Chief Executive Officer

    • Tenure: 0yrs
    • Compensation: €60.63k
  • Régis Brun (65yo)

    Vice-Chairman of the Board of Directors and Deputy Chief Executive Officer

    • Tenure: 0yrs
    • Compensation: €22.94k

Board Members

  • Viviane Neiter (61yo)

    Director

    • Tenure: 0yrs
  • Thierry Chapusot (60yo)

    Director

    • Tenure: 0yrs
  • Michel Salmon

    Director

    • Tenure: 1.4yrs
  • Jean-Yves Ravinet (62yo)

    Director

    • Tenure: 1.4yrs
  • Frederic Bourgaud (55yo)

    Vice-Chairman of the Board of Directors & Deputy CEO

    • Tenure: 0yrs
    • Compensation: €11.81k
  • Paul Hannewald (39yo)

    Deputy Chief Executive Officer and Director

    • Tenure: 0yrs
    • Compensation: €53.14k
  • Eric Gontier

    Director

    • Tenure: 0yrs
  • Jean-Paul Fevre (65yo)

    Chairman & Chief Executive Officer

    • Tenure: 0yrs
    • Compensation: €60.63k
  • Régis Brun (65yo)

    Vice-Chairman of the Board of Directors and Deputy Chief Executive Officer

    • Tenure: 0yrs
    • Compensation: €22.94k
  • Thierry Fevre

    Director

    • Tenure: 0yrs

Company Information

Plant Advanced Technologies SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Plant Advanced Technologies SA
  • Ticker: ALPAT
  • Exchange: ENXTPA
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €14.988m
  • Shares outstanding: 973.26k
  • Website: https://www.plantadvanced.com

Number of Employees


Location

  • Plant Advanced Technologies SA
  • 19, avenue de la forêt de Haye
  • Vandœuvre-lès-Nancy
  • Lorraine
  • 54500
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALPATENXTPA (Euronext Paris)YesCommon StockFREURAug 2009

Biography

Plant Advanced Technologies SA, a plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France. Its technologies include PAT Plant Milking that p ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/20 21:09
End of Day Share Price2019/11/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.